Monoclonal antibodies for chronic refractory asthma and pipeline developments

Drug Discovery Today

Volumn 17, Issue 11-12, 2012, Pages 591-599

  Polosa, Riccardo ^a   Casale, Thomas ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b CREIGHTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 317; ANRUKINZUMAB; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CINQUIL; CORTICOSTEROID; DACLIZUMAB; ENOKIZUMAB; ETANERCEPT; GOLIMUMAB; IDECCE 9.1; IMMUNOGLOBULIN E ANTIBODY; INFLIXIMAB; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; KELIXIMAB; LEBRIKIZUMAB; LONG ACTING BETA AGONIST; LUMILIXIMAB; MEPOLIZUMAB; MILR 1444 R; MONOCLONAL ANTIBODY; OMALIZUMAB; PASCOLIZUMAB; PLACEBO; QAX 576; RESLIZUMAB; RG 7449; T LYMPHOCYTE ANTIGEN; TRALOKINUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ALLERGIC ASTHMA; ASTHMA; ATOPY; BASOPHIL; CELLULAR IMMUNITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DESIGN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; EOSINOPHIL; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE REACTION; MAST CELL; NEUTROPHIL; NONHUMAN; PATHOGENESIS; RESPIRATORY TRACT INFECTION; REVIEW; RISK REDUCTION; SINUSITIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADAPTIVE IMMUNITY; ANIMALS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG RESISTANCE; HUMANS; IMMUNITY, INNATE; SEVERITY OF ILLNESS INDEX;

EID: 84861596408     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.01.012     Document Type: Review

References (75)

1. S.T. Holgate, and R. Polosa The mechanisms, diagnosis, and management of severe asthma in adults Lancet 368 2006 780 793
2. W.C. Moore Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program Am. J. Respir. Crit. Care Med. 181 2010 315 323
3. J. Lötvall Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome J. Allergy Clin. Immunol. 127 2011 355 360
4. British Thoracic Society Scottish Intercollegiate Guidelines Network BTS/SIGN British guideline on management of asthma Thorax 63 Suppl. 4 2008 1 121
5. R. Polosa An overview of chronic severe asthma Intern. Med. J. 38 2008 190 198
6. D.H. Smith A national estimate of the economic costs of asthma Am. J. Respir. Crit. Care Med. 156 1997 787 793
7. P. Godard Costs of asthma are correlated with severity: a 1-yr prospective study Eur. Respir. J. 19 2002 61 67
8. L. Antoncelli Asthma severity and medical resource utilization Eur. Respir. J. 23 2004 723 729
9. P. Chanez Severe asthma in adults: what are the important questions? J. Allergy Clin. Immunol. 119 2007 1337 1348
10. R. Polosa, and G.T. Benfatto Managing patients with chronic severe asthma: rise to the challenge Eur. J. Intern. Med. 20 2009 114 124
11. G.P. Currie Difficult to treat asthma in adults BMJ 338 2009 494
12. J.B. Morjaria, and R. Polosa Recommendation for optimal management of severe refractory asthma J. Asthma Allergy 3 2010 43 56
13. S.T. Holgate, and R. Polosa Treatment strategies for allergy and asthma Nat. Rev. Immunol. 8 2008 218 230
14. D. Robinson Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma N. Engl. J. Med. 326 1992 298 304
15. M. Cazzola, and R. Polosa Anti-TNF-alfa and Th1 cytokine-directed therapies for the treatment of asthma Curr. Opin. Allergy Clin. Immunol. 6 2006 43 50
16. A. Thorburn, and P. Hansbro Harnessing regulatory T cells to suppress asthma: from potential to therapy Am. J. Respir. Cell. Mol. Biol. 43 2010 511 519
17. W. Wang Potential therapeutic targets for steroid-resistant asthma Curr. Drug Targets 11 2010 957 970
18. P.J. Hudson, and C. Souriau Engineered antibodies Nat. Med. 9 2003 129 134
19. D.A. Scheinberg, and P.B. Chapman Therapeutic applications of monoclonal antibodies for human disease J.R. Birch, E.S. Lennox, Monoclonal Antibodies, Principles and Practice 1995 Wiley-Liss New York 45 105
20. H.J. Gould, and B.J. Sutton IgE in allergy and asthma today Nat. Rev. Immunol. 8 2008 205 217
21. J. Corne The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety and pharmacokinetics J. Clin. Invest. 99 1997 879 887
22. J. Patou Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in nasal polyps J. Allergy Clin. Immunol. 121 2008 110 115
23. J.B. Morjaria, and R. Polosa Off-label use of omalizumab in non-asthma conditions: new opportunities Expert Rev. Resp. Med. 3 2009 299 308
24. T.B. Casale, and J. Stokes Anti-IgE therapy: clinical utility beyond asthma J. Allergy Clin. Immunol. 123 2009 770 771
25. R.L. Shields Inhibition of allergic reactions with antibodies to IgE Int. Arch. Allergy Immunol. 107 1995 308 312
26. R. Polosa, and S.T. Holgate Omalizumab and Severe Allergic Asthma 2009 Clinical Publishing Oxford
27. S. Walker Anti-IgE for chronic asthma in adults and children (update) Cochrane Database Syst. Rev. 2 2006 CD003559
28. B. Lanier Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma J. Allergy Clin. Immunol. 124 2009 1210 1216
29. Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention 2009 Available at: http://www.ginasthma.org
30. C. Domingo Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients Curr. Med. Res. Opin. 27 2011 45 53
31. A.K. Zaidi Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab J. Allergy Clin. Immunol. 125 2010 902 908
32. L.J. Rosenwasser Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial J. Allergy Clin. Immunol. 112 2003 563 570
33. C. Russo, and R. Polosa TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis Clin. Sci. 109 2005 135 142
34. J.B. Morjaria Biologic and pharmacologic therapies in clinical development for the inflammatory response in COPD Drug Discov. Today 15 2010 396 405
35. E. Erin The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma Am. J. Respir. Crit. Care Med. 174 2006 753 762
36. S.E. Wenzel A randomized, double-blind, placebo-controlled study of tumor necrosis factoralpha blockade in severe persistent asthma Am. J. Respir. Crit. Care Med. 179 2009 549 558
37. P.H. Howarth Tumour necrosis factor (TNF{alpha}) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma Thorax 60 2005 1012 1018
38. M.A. Berry Evidence of a role of tumor necrosis factor alpha in refractory asthma N. Engl. J. Med. 354 2006 697 708
39. J.B. Morjaria The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised placebo-controlled trial Thorax 63 2008 584 591
40. S.T. Holgate Efficacy/safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial Eur. Respir. J. 37 2011 1352 1359
41. M.E. Rothenberg, and S.P. Hogan The eosinophil Annu. Rev. Immunol. 24 2006 147 174
42. P. Flood-Page Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics J. Clin. Invest. 112 2003 1029 1036
43. H. Tanaka Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice Am. J. Respir. Cell. Mol. Biol. 31 2004 62 68
44. C.J. Sanderson Interleukin-5, eosinophils, and disease Blood 79 1992 3101 3109
45. P. Flood-Page A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma Am. J. Respir. Crit. Care Med. 176 2007 1062 1071
46. P.T. Flood-Page Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway Am. J. Respir. Crit. Care Med. 167 2003 199 204
47. M.J. Leckie Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response Lancet 356 2000 2144 2148
48. P. Nair Mepolizumab for prednisone-dependent asthma with sputum eosinophilia N. Engl. J. Med. 360 2009 985 993
49. P. Haldar Mepolizumab and exacerbations of refractory eosinophilic asthma N. Engl. J. Med. 360 2009 973 984
50. R. Polosa, and J. Morjaria Immunomodulatory and biologic therapies for severe refractory asthma Respir. Med. 102 2008 1499 1510
51. W.W. Busse Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma J. Allergy Clin. Immunol. 125 2010 1237 1244
52. C.K. Oh Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma Eur. Respir. Rev. 19 2010 46 54
53. P. Hart Differential responses of human monocytes and macrophages to IL-4 and IL-13 J. Leukoc. Biol. 66 1999 575 578
54. G.K. Hershey IL-13 receptors and signaling pathways: an evolving web J. Allergy Clin. Immunol. 111 2003 677 690
55. L.C. Borish Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo controlled trial Am. J. Respir. Crit. Care Med. 160 1999 1816 1823
56. L.C. Borish Efficacy of soluble IL-4 receptor for the treatment of adults with asthma J. Allergy Clin. Immunol. 107 2001 963 970
57. T.K. Hart Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized antiinterleukin-4 antibody with therapeutic potential in asthma Clin. Exp. Immunol. 130 2002 93 100
58. G.M. Gauvreau The effects of IMA-638 on allergen induced airway responses in subjects with mild atopic asthma Eur. Respir. J. 32 Suppl. 52 2008 827
59. G.M. Gauvreau Effects of Interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma Am. J. Respir. Crit. Care Med. 183 2011 1007 1014
60. H.H. Kariyawasam Effects of anti-IL-13 (Novartis QAX576) on inflammatory responses following nasal allergen challenge (NAC) Am. J. Respir. Crit. Care Med. 179 2009 3642
61. D. Singh A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma BMC Pulm. Med. 10 2010 3
62. J. Corren Lebrikizumab treatment in adults with asthma N. Engl. J. Med. 365 2011 1088 1098
63. N. Fitch Preclinical evaluation of BAY 16-9996 a dual IL-4/IL-13 receptor antagonist J. Allergy Clin. Immunol. 107 Suppl. 2001 331 339
64. S. Wenzel Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies Lancet 370 2007 1422 1431
65. M.R. Hodges Randomized, double-blind, placebo controlled first in human study of inhaled AIR645, an IL-4Rα oligonucleotide, in healthy volunteers Am. J. Respir. Crit. Care Med. 179 2009 3640
66. J. Corren A randomized, controlled, phase 2 study of AMG 317, an IL-4Rα antagonist, in patients with asthma Am. J. Respir. Crit. Care Med. 181 2010 788 796
67. R.C. Levitt IL-9 pathway in asthma: new therapeutic targets for allergic inflammatory disorders J. Allergy Clin. Immunol. 103 1999 485 491
68. C.K. Oh Biology of IL-9 pathway and its therapeutic potential for the treatment of asthma Inflamm. Allergy Drug Targets 10 2011 180 186
69. J. Parker Randomized, double-blind, placebo-controlled, multicenter Phase 2A study to evaluate the effect of a humanized Interleukin-9 monoclonal antibody (MEDI-528) on exercise-induced bronchospasm Am. J. Respir. Crit. Care Med. 181 2010 5394
70. Y.H. Wang, and Y.J. Liu OX40-OX40L interactions: a promising therapeutic target for allergic diseases? J. Clin. Invest. 117 2007 3655 3657
71. A. Hoshino Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma Eur. J. Immunol. 33 2003 861 869
72. O.M. Kon The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ Tcells in asthma Eur. Respir. J. 18 2001 45 52
73. O.M. Kon Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma Lancet 352 1998 1109 1113
74. M. Azzawi T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis Am. Rev. Respir. Dis. 145 1992 1477 1482
75. W.W. Busse Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial Am. J. Respir. Crit. Care Med. 178 2008 1002 1008